Most Recent
Construction PRO
Lendlease chair John Gillam has said the company's board was “deeply discontented” with KPMG’s alleged misuse of its confidential information but was stuck with the accounting firm until the end of the financial year.
SkyCity has agreed to pay a $21 million fine in an agreement with the South Australian gambling authority following an inquiry by former Supreme Court Justice Brian Martin which found historical compliance and governance failures.
The lead shareholder in class actions against CBA has urged the High Court to take a "common sense" approach to loss causation in securities cases, as endorsed by the Full Federal Court in last month's ruling for Worley's investors.
Construction PRO
Super fund trustee REST Nominees is the first of the Dexus bloc of APAC shareholders to challenge a finding that a default notice issued by the board of the airport operator was valid.
Construction PRO
Building giant Lendlease has told besieged auditor KPMG it expects to be compensated for the cost of dealing with the fallout of the accounting giant's misuse of its confidential data.
Law firm Allens has told a parliamentary committee that a court should weigh in on whether parliament's powers to compel information overrode KPMG's legal privilege, as the auditor resists orders to produce documents.
Former directors of failed clothing retailer Mosaic Brands are claiming privilege over retainer letters between Deloitte and the company as special purpose liquidators investigate potential insolvent trading and directors duty breach claims.
Honda has succeed in challenging a $13.6 million damages award to a former dealer whose contract was broken when the car maker transitioned away from a dealer model.
A former financial advisor and his company have won court approval to run a claim challenging AMP's buyer of last resort policy, despite the company being a group member in a related class action that settled for $100 million in 2023.
Swiss drug maker Novartis has lost its bid to have Pharmacor's Valtresto trade mark removed for non use, with an IP Australia delegate finding that an injunction in a fight over the patent for Novartis' heart drug Entresto was an obstacle to using the mark.